News Related to Psoriatic Disease

Related coverage linked through entity extraction aliases.

Lilly reports Phase IIIb psoriasis trial met dual skin clearance and weight-loss endpoint

May 14, 2026

Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.

Pharmaceutical Stocks to Watch Include Eli Lilly, AbbVie, Vertex, Gilead and Pfizer

Apr 23, 2026

Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.